CERo Therapeutics Holdings, Inc. Common Stock Cash Flow-to-Debt Ratio
CERo Therapeutics Holdings, Inc. Common Stock cash flow-to-debt ratio. CERo Therapeutics Holdings, Inc. Common Stock (CERO) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2026, meaning its operating cash flow of $-2.33 Million could theoretically repay 0% of its total liabilities ($32.41 Million) in one year. Check CERO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of CERo Therapeutics Holdings, Inc. Common Stock (2021–2025)
Cash flow-to-debt ratio of CERo Therapeutics Holdings, Inc. Common Stock from 2021 to 2025. Historical debt coverage capacity for CERo Therapeutics Holdings, Inc. Common Stock across 5 annual periods. Also explore CERO net asset momentum to track the company's year-over-year net asset growth rate.
CERo Therapeutics Holdings, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2021–2025)
CERo Therapeutics Holdings, Inc. Common Stock cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for CERo Therapeutics Holdings, Inc. Common Stock. For the full cash flow conversion analysis, see CERo Therapeutics Holdings, Inc. Common (CERO) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.77x | $-16.08 Million | $9.09 Million | ▼ -147.6% |
| 2024 | -0.71x | $-5.79 Million | $8.10 Million | ▼ -482.4% |
| 2023 | -0.12x | $-5.79 Million | $47.18 Million | ▼ -348.2% |
| 2022 | -0.03x | $-1.09 Million | $39.90 Million | ▲ +63.7% |
| 2021 | -0.08x | $-697.11K | $9.25 Million | — |